Sai Life Sciences Ltd
07 Nov 2026 12:00 AM
Sai Life Sciences Ltd consolidated sales up 18.82% on year in Q2FY2027, net profit jumped 34.15%,
Sai Life Sciences Ltd share price rallied 11.83% to Rs 1785.0 after the company`s net profit saw a strong growth of 34.15% to Rs 98.32 crore, while revenue from operations increased 18.82% to Rs 658.59 crore in Q2FY27 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.82 lakh crore, rising 5.54%. It has improved by 2.89% over last one week and crept higher by 3.43% in last one month while the market capitalization of Sai Life Sciences Ltd has edged up by 14.45% and 31.09% in the same period respectively.
Profit before tax (PBT) of Sai Life Sciences Ltd stood at Rs 131.28 crore in Q2 FY27, expanding by 17.16% year-on-year, and jumping 34.00% quarter-on-quarter. EBITDA came in at Rs 182 crore, surging by 39.78% YoY and rallying 26.26% sequentially.
Total expenses went up by 15.06% to Rs 520.33 crore in Q2FY27 over Q2FY26. During the quarter, cost of materials consumed stood at Rs 170.07 crore, slightly declining by 4.37% YoY, while employee benefits expense was at Rs 198.06 crore, rising by 10.09% YoY.
For FY26, revenue from operations soared by 29.38% to Rs 2192.49 crore, while net profit surged by 105.08% to Rs 348.91 crore, compared to previous FY. EBITDA jumped by 39617% to Rs 582.03 crore, and PBT soared 104.74% to Rs 466.19 crore compared to previous FY.
The company`s consolidated net cash flow from operating activities stood at Rs 509.13 crore in FY26, as against Rs 314.05 crore in FY25.
Sai Life Sciences Ltd soared by 93.58% in last one year, significantly outperforming the benchmark BSE Sensex which has softened by 2.74% during the same period.
Sai Life Sciences Ltd
06 Nov 2026 12:00 AM
Sai Life Sciences Ltd consolidated sales up 18.82% on year in Q3FY2026, net profit surged by 34.15%,
Sai Life Sciences Ltd share price inched up 3.23% to Rs 1596.2 after the company`s net profit soared by 34.15% to Rs 98.32 crore, while revenue from operations edged up 18.82% to Rs 658.59 crore in Q3FY26 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.82 lakh crore, gaining 5.29%. It has improved by 2.18% over last one week and ticked higher by 2.72% in last one month while the market capitalization of Sai Life Sciences Ltd has marginally improved by 2.34% and 17.23% in the same period respectively.
Profit before tax (PBT) of Sai Life Sciences Ltd stood at Rs 131.28 crore in Q3 FY26, surging by 17.16% year-on-year, and jumping 34.00% quarter-on-quarter. EBITDA came in at Rs 182 crore, expanding by 39.78% YoY and rallying 26.26% sequentially.
Total expenses advancing by 15.06% to Rs 520.33 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 170.07 crore, softening by 4.37% YoY, while employee benefits expense was at Rs 198.06 crore, rising by 10.09% YoY.
For the TTM ended FY26, revenue from operations surged 29.38% to Rs 2192.49 crore, while net profit saw a strong growth of 105.08% to Rs 348.91 crore, compared to previous TTM. EBITDA jumped by 39617% to Rs 582.03 crore, and PBT witnessed a strong rise of 104.74% to Rs 466.19 crore compared to previous TTM.
The company`s consolidated net cash flow from operating activities stood at Rs 509.13 crore in FY26, as against Rs 314.05 crore in FY25.
Sai Life Sciences Ltd jumped 73.10% in last one year, significantly outperforming the benchmark BSE Sensex which has softened by 4.80% during the same period.
Sai Life Sciences Ltd
05 Oct 2026 12:00 AM
Sai Life Sciences reported securities dematerialization details to Indian stock exchanges,
Sai Life Sciences Limited informed the National Stock Exchange of India Limited and the BSE Limited that it has certified the details of securities dematerialized/rematerialized during the quarter ended September 30, 2026, as required under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, and furnished them to all stock exchanges where the company is listed, according to a filing on October 5, 2026. KFin Technologies Limited acted as the Registrar to an Issue and Share Transfer Agent for Sai Life Sciences Limited.
Sai Life Sciences Ltd
01 Oct 2026 12:00 AM
Sai Life Sciences to review financial results at board meeting on November 5, 2026,
Sai Life Sciences Limited will hold a board meeting on Thursday, November 5, 2026, to consider and approve the standalone and consolidated unaudited financial results for the second quarter and half year ended September 30, 2026, as well as other corporate matters. The trading window for the company`s securities was closed for designated persons and their immediate relatives from October 1, 2026, and will remain closed until November 7, 2026.
Sai Life Sciences Ltd
28 Sep 2026 12:00 AM
Sai Life Sciences halts securities trading ahead of Q2/H1 2026 results announcement,
Sai Life Sciences Limited will close its trading window for securities from October 1, 2026, until 48 hours after the announcement of its unaudited financial results for the second quarter and half year ending September 30, 2026, in compliance with SEBI’s Prohibition of Insider Trading Regulations and the company’s Code of Conduct.
Subscribe for our
newsletter
newsletter
HSL Mobile App